Bone marrow ablation followed by allogeneic marrow grafting during first complete remission of acute nonlymphocytic leukemia. 1983

S J Forman, and W E Spruce, and M J Farbstein, and J L Wolf, and E P Scott, and A P Nademanee, and J L Fahey, and T Hecht, and J A Zaia, and R A Krance, and D O Findley, and K G Blume

Of 33 patients who had undergone allogeneic bone marrow transplantation during first complete remission of acute nonlymphocytic leukemia, 21 patients have now been followed in continued complete remission for 6-64 mo (median greater than 18 mo) without maintenance chemotherapy. The median age of the surviving patients is 27 yr. Transplant-related complications occurring throughout the first year after marrow grafting were fatal in 7 patients, and leukemic recurrence led to the death of 5 patients. The actuarial long-term disease-free survival is 60% and the actuarial remission rate is 79%.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D010356 Patient Isolation The segregation of patients with communicable or other diseases for a specified time. Isolation may be strict, in which movement and social contacts are limited; modified, where an effort to control specified aspects of care is made in order to prevent cross infection; or reverse, where the patient is secluded in a controlled or germ-free environment in order to protect him or her from cross infection. Home Isolation,Isolation, Home,Isolation, Patient,Negative Pressure Isolation,Negative Pressure Patient Isolation
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014916 Whole-Body Irradiation Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms. Radiation, Whole-Body,Total Body Irradiation,Irradiation, Total Body,Irradiation, Whole-Body,Whole-Body Radiation,Irradiation, Whole Body,Irradiations, Total Body,Irradiations, Whole-Body,Radiation, Whole Body,Radiations, Whole-Body,Total Body Irradiations,Whole Body Irradiation,Whole Body Radiation,Whole-Body Irradiations,Whole-Body Radiations
D016026 Bone Marrow Transplantation The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. Bone Marrow Cell Transplantation,Grafting, Bone Marrow,Transplantation, Bone Marrow,Transplantation, Bone Marrow Cell,Bone Marrow Grafting

Related Publications

S J Forman, and W E Spruce, and M J Farbstein, and J L Wolf, and E P Scott, and A P Nademanee, and J L Fahey, and T Hecht, and J A Zaia, and R A Krance, and D O Findley, and K G Blume
November 1988, Blood,
S J Forman, and W E Spruce, and M J Farbstein, and J L Wolf, and E P Scott, and A P Nademanee, and J L Fahey, and T Hecht, and J A Zaia, and R A Krance, and D O Findley, and K G Blume
March 1987, Transplantation,
S J Forman, and W E Spruce, and M J Farbstein, and J L Wolf, and E P Scott, and A P Nademanee, and J L Fahey, and T Hecht, and J A Zaia, and R A Krance, and D O Findley, and K G Blume
October 1991, Blood,
S J Forman, and W E Spruce, and M J Farbstein, and J L Wolf, and E P Scott, and A P Nademanee, and J L Fahey, and T Hecht, and J A Zaia, and R A Krance, and D O Findley, and K G Blume
July 1973, Biomedicine / [publiee pour l'A.A.I.C.I.G.],
S J Forman, and W E Spruce, and M J Farbstein, and J L Wolf, and E P Scott, and A P Nademanee, and J L Fahey, and T Hecht, and J A Zaia, and R A Krance, and D O Findley, and K G Blume
June 1992, Blood,
S J Forman, and W E Spruce, and M J Farbstein, and J L Wolf, and E P Scott, and A P Nademanee, and J L Fahey, and T Hecht, and J A Zaia, and R A Krance, and D O Findley, and K G Blume
April 1997, Blood,
S J Forman, and W E Spruce, and M J Farbstein, and J L Wolf, and E P Scott, and A P Nademanee, and J L Fahey, and T Hecht, and J A Zaia, and R A Krance, and D O Findley, and K G Blume
January 1990, Bone marrow transplantation,
S J Forman, and W E Spruce, and M J Farbstein, and J L Wolf, and E P Scott, and A P Nademanee, and J L Fahey, and T Hecht, and J A Zaia, and R A Krance, and D O Findley, and K G Blume
February 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S J Forman, and W E Spruce, and M J Farbstein, and J L Wolf, and E P Scott, and A P Nademanee, and J L Fahey, and T Hecht, and J A Zaia, and R A Krance, and D O Findley, and K G Blume
January 1981, Haematology and blood transfusion,
S J Forman, and W E Spruce, and M J Farbstein, and J L Wolf, and E P Scott, and A P Nademanee, and J L Fahey, and T Hecht, and J A Zaia, and R A Krance, and D O Findley, and K G Blume
May 1985, Blood,
Copied contents to your clipboard!